US 11,753,436 B2
Analogs of celastrol
Ralph Mazitschek, Belmont, MA (US); Yanbing Ding, Richmond (CA); and Kaisheng Shen, Shanghai (CN)
Assigned to ERX Pharmaceuticals Corporation, Cambridge, MA (US)
Filed by ERX Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 15, 2020, as Appl. No. 16/849,554.
Application 16/849,554 is a continuation of application No. 15/771,077, granted, now 10,662,218, previously published as PCT/US2016/058313, filed on Oct. 21, 2016.
Claims priority of provisional application 62/245,356, filed on Oct. 23, 2015.
Prior Publication US 2021/0061851 A1, Mar. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/56 (2006.01); A61K 31/58 (2006.01); C07C 13/62 (2006.01); C07J 63/00 (2006.01); A61P 3/04 (2006.01)
CPC C07J 63/008 (2013.01) [A61K 31/56 (2013.01); A61K 31/58 (2013.01); A61P 3/04 (2018.01)] 14 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or prodrug thereof, wherein
the dotted lines between C1 and C2, C2 and R3, C3 and R4, C5 and C6, C5 and C7, C1 and C6, and C3 and C4 indicate that a single or double bond may be present, as valence permits;
R1 is —NHR5, —NR5R5, —NHCOR5, —NR5COR5, —NHSO2R5, or —NR5SO2R5;
R2 is —H, —CH3, —SCH(CH3)2, —SC(═O)CH3, —SC(═O)R5, —SCH2CH2OCOCH3, —SR5, —SOR5, —SOOR5, —SCONR5R5,

OG Complex Work Unit Chemistry
R3 is —OCOCH3, —OCOOCH2CH3, —OR7, —R7, or —NR5R5 when a double bond is present between C1 and C2, C3 and C4, and C5 and C6
R4 is —OCOCH3, —OCOOCH2CH3, —OR7, —R7, or —NR5R5 when a double bond is present between C1 and C2, C3 and C4, and C5 and C6;
R3 is O when R4 is O and a double bond is present between C2 and R3 and C3 and R4;
R4 is —OCH3, —OP(═O)(OCH3)2, —OH, —OCOOCH2CH3, —OCONHCH2CH3, —OCOOCH(CH3)2, —OR7, —R7, or —NR5R5 when R3 is O and a double bond is present between C2 and R3;
R5 is independently selected for each occurrence from hydrogen, an alkyl, cycloalkyl, and aryl; and
R7 is hydrogen, methyl, or ethyl.